Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042
Source: Vaccine - Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research
More News: Allergy & Immunology | China Health | Clinical Trials | Influenza | Influenza Vaccine | Occupational Health | Study | Vaccines